+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Expanded colesevelam administration options with oral suspension formulation for patients with diabetes and hypercholesterolemia



Expanded colesevelam administration options with oral suspension formulation for patients with diabetes and hypercholesterolemia



Postgraduate Medicine 126(3): 126-134



Colesevelam HCl (colesevelam) is a bile acid sequestrant initially approved by the US Food and Drug Administration (FDA) in 2000 as an adjunct to diet and exercise to lower elevated low-density lipoprotein cholesterol (LDL-C) levels in adults with primary lipidemia, as monotherapy, or in combination with a statin. More recently, the drug was approved for use in adults with type 2 diabetes mellitus (T2DM) to improve glycemic control. Thus, colesevelam is currently the only single-agent monotherapy approved by the FDA to lower both LDL-C and glycated hemoglobin (A1c) levels in adults with T2DM and elevated LDL-C. Moreover, the formulation options for colesevelam have also expanded since its original approval. A Medline search was conducted to provide evidence to support the efficacy and safety for the use of colesevelam tablets or oral suspension preparations when treating patients with lipidemia, T2DM, or both. No limitations were placed on publication date or any other parameter. Clinical studies have shown that colesevelam is efficacious in lowering LDL-C levels, improving the lipid profile, and improving glycemic control by reducing both A1c and fasting plasma glucose levels in T2DM. Equilibrium and kinetics data show that colesevelam is equivalent in its tablet and oral suspension formulation. Having 2 effective oral routes enhances convenience and improves compliance, both of which contribute to maximal therapeutic outcomes. These compliance benefits are due to the ease and flexibility of preparing the powder in various beverages and the pleasant taste from the inclusion of a low-calorie citrus flavoring.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 053121928

Download citation: RISBibTeXText

PMID: 24918798

DOI: 10.3810/pgm.2014.05.2762


Related references

Colesevelam hydrochloride powder for oral suspension versus cholestyramine powder for oral suspension: comparison of acceptability and tolerability. Endocrine Practice 17(2): 218-225, 2011

The role of colesevelam hydrochloride in hypercholesterolemia and type 2 diabetes mellitus. Annals of PharmacoTherapy 44(7-8): 1196-1206, 2010

Colesevelam: an improved bile acid sequestrant for treating hypercholesterolemia and improving diabetes. Expert Review of Endocrinology & Metabolism 5(6): 825-834, 2010

Colesevelam: an improved bile acid sequestrant for treating hypercholesterolemia and improving diabetes. Expert Review of Endocrinology and Metabolism 5(6): 825-834, 2010

Colesevelam hydrochloride: evidence for its use in the treatment of hypercholesterolemia and type 2 diabetes mellitus with insights into mechanism of action. Core Evidence 7: 61-75, 2012

Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix™) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007. Vaccine 29(11): 2029-2036, 2011

Colesevelam: in pediatric patients with heterozygous familial hypercholesterolemia. Paediatric Drugs 12(2): 133-140, 2010

Comparison of the relative bioavailability and pharmacokinetics of estrone after oral administration of esterified estrogens in a tablet formulation and an aqueous suspension. Arzneimittel-Forschung 47(2): 208-212, 1997

Multivariate analysis of factors associated with persistent colesevelam treatment among patients with hypercholesterolemia. Annals of PharmacoTherapy 47(10): 1247-1252, 2013

Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. American Journal of Medicine 110(5): 352-360, 2001

Effects of colesevelam hydrochloride (WelChol) on biomarkers of inflammation in patients with mild hypercholesterolemia. American Journal of Cardiology 98(5): 641-643, 2006

Effects of colesevelam HC1 on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. Digestive Diseases and Sciences 50(7): 1232-1238, 2005

The efficacy of colesevelam HCl in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients. Clinical Therapeutics 35(8): 1247-1252, 2013

Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes. Current Medical Research and Opinion 25(9): 2239-2249, 2009

Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia. American Journal of Therapeutics 12(4): 306-310, 2005